Product Description
Vicagrel is a new antiplatelet pro-drug based on clopidogrel sulfur lactone metabolites. Vicagrel at 40 to 75 mg inhibits ADP-induced platelet aggregation, with a fast onset of action and significantly greater potency than clopidogrel. Vicagrel may be a highly effective and well-tolerated antiplatelet agent. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004678/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jiangsu vcare pharmaceutical technology
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Coronary Syndrome
Phase 1: Coronary Artery Disease|Coronary Disease|Myocardial Infarction|Peripheral Arterial Disease|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20252799 |
CTR20252799 | P1 |
Completed |
Myocardial Infarction|Peripheral Arterial Disease|Acute Coronary Syndrome|Coronary Disease|Stroke |
2025-08-22 |
2025-08-31 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT07067775 |
VCP1-I-09 | P1 |
Completed |
Acute Coronary Syndrome |
2025-08-22 |
50% |
2025-09-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
CTR20244838 |
CTR20244838 | P1 |
Completed |
Myocardial Infarction|Peripheral Arterial Disease|Stroke|Coronary Disease|Acute Coronary Syndrome |
2024-07-09 |
2025-08-24 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20222479 |
CTR20222479 | P1 |
Recruiting |
Acute Coronary Syndrome|Coronary Artery Disease|Myocardial Infarction|Stroke |
None |
2025-04-29 |
||
NCT06577519 |
VCP1-III-01 | P3 |
Recruiting |
Acute Coronary Syndrome |
2026-12-30 |
4% |
2024-10-02 |